Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|177|6|1503-1509

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.177, Iss.6, 2017-12, pp. : 1503-1509

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 571-571

John Wiley & Sons Inc

Access to resources Recommend Favorite

Brentuximab vedotin is an effective therapy for CD30+ mycosis fungoides and cutaneous anaplastic large‐cell lymphoma: what is the cost?

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1474-1475

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T‐cell lymphoma: reply from the authors

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 303-303

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T‐cell lymphoma

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 302-303

John Wiley & Sons Inc

Access to resources Recommend Favorite

How we diagnose and treat essential thrombocythaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 3, 2015-11 ,pp. : 306-321

John Wiley & Sons Inc

Access to resources Recommend Favorite